Posterior Cortical Atrophy

Migration, Crosslink

📖

Posterior Cortical Atrophy

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-posterior-cortical-atrophy

📖 Wiki Page

disease3290 wordssynced 2026-04-02

Posterior Cortical Atrophy

Introduction

Posterior Cortical Atrophy (PCA) is a rare neurodegenerative disorder characterized by progressive decline in visual processing and other posterior cortical functions. It is often considered a variant of [Alzheimer's disease](/diseases/alzheimers-disease) but presents with distinct clinical and neuroimaging features. Also known as Benson syndrome, PCA represents a distinct clinical syndrome that primarily affects the visual processing regions of the brain, leading to progressive visual impairment while other cognitive functions remain relatively preserved in the early stages. [@crutch2017]

Epidemiology

PCA typically presents in individuals aged 50-65 years, which is earlier than typical [Alzheimer's disease](/diseases/alzheimers-disease). The prevalence is estimated at 5-10% of early-onset dementia cases, though this may be an underestimate due to misdiagnosis. There appears to be no significant gender preference, and most cases are sporadic, though familial cases have been reported. [@mendez2019]

Recent population-based studies suggest the true prevalence may be higher than previously estimated, with some studies suggesting up to 12% of early-onset dementia cases meeting criteria for PCA. [@schott2020] The disease typically progresses over 8-12 years, with eventual involvement of anterior brain regions in later stages.

Clinical Presentation

Core Symptoms

Patients with PCA present with a characteristic constellation of symptoms centered on visual processing deficits:

...

Posterior Cortical Atrophy

Introduction

Posterior Cortical Atrophy (PCA) is a rare neurodegenerative disorder characterized by progressive decline in visual processing and other posterior cortical functions. It is often considered a variant of [Alzheimer's disease](/diseases/alzheimers-disease) but presents with distinct clinical and neuroimaging features. Also known as Benson syndrome, PCA represents a distinct clinical syndrome that primarily affects the visual processing regions of the brain, leading to progressive visual impairment while other cognitive functions remain relatively preserved in the early stages. [@crutch2017]

Epidemiology

PCA typically presents in individuals aged 50-65 years, which is earlier than typical [Alzheimer's disease](/diseases/alzheimers-disease). The prevalence is estimated at 5-10% of early-onset dementia cases, though this may be an underestimate due to misdiagnosis. There appears to be no significant gender preference, and most cases are sporadic, though familial cases have been reported. [@mendez2019]

Recent population-based studies suggest the true prevalence may be higher than previously estimated, with some studies suggesting up to 12% of early-onset dementia cases meeting criteria for PCA. [@schott2020] The disease typically progresses over 8-12 years, with eventual involvement of anterior brain regions in later stages.

Clinical Presentation

Core Symptoms

Patients with PCA present with a characteristic constellation of symptoms centered on visual processing deficits:

Visual acuity problems: Despite normal eye examinations, patients report difficulty reading, especially small print
Object recognition deficits: Difficulty identifying objects, faces (prosopagnosia), and places
Spatial disorientation: Problems with navigation, judging distances, and finding items in familiar environments
Reading difficulty: Letters seem to move or disappear, difficulty following lines of text
Color perception changes: Reduced ability to perceive and differentiate colors
Visuospatial neglect: Inattention to one side of visual space
Elemental visual disturbances: Difficulty with motion perception, depth perception, and form discrimination

Patients often present first to ophthalmologists due to visual complaints, leading to delayed diagnosis. The dissociation between preserved visual acuity on testing and significant functional visual impairment is a key diagnostic clue. [@benson1988]

Balint's Syndrome

Many PCA patients develop features of Balint's syndrome, a disorder of simultaneous visual processing:

Simultagnosia: Inability to perceive more than one object at a time, leading to difficulty with complex visual scenes
Optic ataxia: Difficulty reaching for objects under visual guidance, with misreaching to targets
Gaze apraxia: Difficulty voluntarily directing gaze toward objects, requiring head movements to compensate

The presence of Balint's syndrome strongly suggests posterior cortical involvement and is a hallmark of PCA. [@kas2013]

Gerstmann Syndrome

PCA can also present with features of Gerstmann syndrome:

Agraphia: Difficulty writing, particularly with letter formation
Acalculia: Difficulty with arithmetic calculations, even with simple operations
Finger agnosia: Inability to identify fingers on one's own hand
Left-right disorientation: Confusion distinguishing left from right

Additional Clinical Features

Beyond the classic syndromes, PCA patients may exhibit:

Dressing apraxia: Inability to orient clothing correctly when dressing
Constructional apraxia: Difficulty copying or drawing simple figures
Ideomotor apraxia: Impaired ability to execute learned motor tasks on command
Environmental disorientation: Getting lost in familiar surroundings
Face recognition deficits: Progressive prosopagnosia for familiar and unfamiliar faces
Color anomia: Inability to name colors despite intact color perception

Disease Comparison

| Feature | PCA | Typical AD | Logopenic PPA | Posterior Cortical Dementia |
|---------|-----|------------|----------------|----------------------------|
| Primary Deficit | Visuospatial | Memory | Language | Visual |
| Memory Early | Preserved | Impaired | Variable | Preserved |
| Occipitoparietal Atrophy | Severe | Mild | Variable | Severe |
| Amyloid PET | Positive (80%) | Positive | Variable | Variable |
| Age of Onset | 50-65 years | 65+ years | 60-70 years | 50-65 years |
| Visual Symptoms | Prominent early | Late | Variable | Prominent |
| Language | Preserved early | Impaired | Impaired | Preserved |
| Progression Rate | Moderate | Variable | Moderate | Variable |

PCA differs from typical AD in several important ways. Memory function is typically preserved in the early stages, with visual symptoms predominating. The atrophy pattern favors posterior brain regions, particularly the occipital and parietal lobes, while the medial temporal lobes remain relatively preserved until later stages. [@migliaccio2012]

Neuroimaging

MRI Findings

MRI imaging reveals characteristic patterns in PCA:

Posterior cortical atrophy: Bilateral but often asymmetric atrophy (right > left) in occipital, parietal, and posterior temporal regions
Posterior cingulate involvement: Degeneration of the precuneus and posterior cingulate [cortex](/brain-regions/cortex)
Preserved medial temporal lobes: Relative preservation of [hippocampus](/brain-regions/hippocampus) and [entorhinal cortex](/brain-regions/entorhinal-cortex) in early stages, distinguishing PCA from typical AD
Occipital pole sparing: Relative preservation of primary visual cortex until later stages
Superior parietal lobule: Significant atrophy in the dorsal visual stream regions
Posterior temporal regions: Involvement of the inferior temporal cortex affecting object recognition

The atrophy pattern in PCA follows the distribution of the dorsal and ventral visual streams, with relative sparing of primary visual cortex until late disease stages. [@matsumoto2015]

PET Findings

Functional imaging shows characteristic patterns:

Hypometabolism: Reduced glucose metabolism in posterior cortical regions on FDG-PET, particularly in the occipital and parietal lobes
Posterior cingulate involvement: Particularly affecting the precuneus, a key hub in the default mode network
Amyloid deposition: Positive amyloid PET in approximately 80% of cases, indicating underlying AD pathology
[Tau](/proteins/tau) PET: Elevated [tau](/proteins/tau) binding in posterior cortical regions, often more prominent than in typical AD

FDG-PET patterns in PCA often show a characteristic "occipital predominant" hypometabolism pattern that can help differentiate it from typical AD. [@bae2016]

Functional Connectivity

Resting-state fMRI studies reveal disrupted connectivity in:

Dorsal attention network: Related to visuospatial processing deficits
Visual networks: Primary and secondary visual cortex disconnection
Default mode network: Precuneus and posterior cingulate dysfunction
Frontoparietal networks: Reduced connectivity associated with executive dysfunction in later stages

The network-based degeneration pattern suggests that PCA may spread through connected brain networks rather than following traditional neuropathological staging. [@fischer2019]

Pathophysiology

Underlying Pathology

Primary pathology: Alzheimer's-type amyloid and [tau](/proteins/tau) pathology in most cases
Tau distribution: Predominant tau pathology in posterior cortical regions, following a pattern distinct from typical AD
Amyloid: Variable amyloid deposition, present in majority but not all cases (approximately 80%)
Pattern: Subcortical sparing relative to typical AD
Cortical layer involvement: Relative sparing of Layer 2 compared to typical AD

The tau pathology in PCA shows a distinctive pattern with greater involvement of the occipital and parietal cortices compared to typical AD. This may reflect different vulnerability of neuronal populations in these regions. [@safirstein2020]

Neurotransmitter Deficits

Cholinergic involvement: Similar to AD, cholinergic neuron loss in the nucleus basalis of Meynert
GABAergic dysfunction: Excitatory-inhibitory imbalance may contribute to visual symptoms
Serotonergic changes: May be involved in mood and behavioral symptoms
Dopaminergic changes: May contribute to any parkinsonian features

The cholinergic deficit in PCA appears similar in magnitude to typical AD, supporting the use of cholinesterase inhibitors. [@whitwell2017]

Genetic Factors

[APOE](/proteins/apoe-protein): Higher frequency of [APOE](/proteins/apoe-protein) ε4 allele compared to controls (approximately 60% of patients)
[PSEN1](/genes/psen1)/APP: Rare mutations can cause PCA phenotypes
TPMT: Recent studies suggest potential genetic associations
GRN (Progranulin): May be associated with atypical presentations
MAPT: Some evidence for tau gene involvement

Genetic studies suggest that PCA may have both shared and distinct genetic risk factors from typical AD. [@caroppo2019]

Biomarkers and Diagnostic Markers

Neuroimaging Biomarkers

| Finding | Modality | Significance |
|---------|----------|--------------|
| Posterior cortical atrophy | MRI | Loss of brain volume in occipital/parietal regions |
| Hypometabolism | FDG-PET | Reduced glucose metabolism in posterior regions |
| Reduced connectivity | fMRI | Disconnection between visual and spatial networks |
| Amyloid deposition | Amyloid PET | Indicates underlying AD pathology |
| Tau accumulation | Tau PET | Posterior cortical tau burden |

CSF Biomarkers

Reduced [Aβ42](/proteins/amyloid-beta): Indicates amyloid pathology in PCA patients
Elevated total tau: Reflects neurodegeneration
Elevated phospho-tau: Specific for tau pathology
Neurofilament light chain (NfL): Elevated in serum and CSF, marker of axonal damage
YKL-40: Chitinase-3-like protein 1, marker of neuroinflammation

The CSF biomarker profile in PCA is generally similar to typical AD, with reduced Aβ42 and elevated tau. However, the tau/Aβ42 ratio may be higher in PCA, reflecting the greater tau burden. [@miller2018]

Blood-Based Biomarkers

Recent advances in blood-based biomarkers show promise for PCA:

Plasma Aβ42/40 ratio: Reduced ratio suggests amyloid pathology
Plasma tau (p-tau181, p-tau217): Elevated levels reflect tau pathology
Plasma NfL: Elevated in neurodegeneration
Plasma GFAP: Astrocyte activation marker

Blood-based biomarkers offer promise for screening and monitoring, though validation in PCA is ongoing. [@cullen2021]

Diagnosis

Clinical Criteria

The diagnosis of PCA is based on:

Progressive visual processing impairment: Core feature, including visual field deficits, object recognition problems, spatial disorientation

Relative preservation of other cognitive functions: Memory, language, executive function relatively intact early

MRI evidence: Posterior cortical atrophy in occipital, parietal, or posterior temporal regions

PET evidence: Posterior hypometabolism on FDG-PET

Onset age: Typically 50-65 years

The clinical criteria have been refined through international consensus studies, improving diagnostic accuracy. [@dubois2021]

Diagnostic Workup

Neurological examination: Rule out ocular causes, assess visual fields
Neuropsychological testing: Document visuospatial deficits, assess multiple cognitive domains
MRI brain: Assess atrophy pattern, rule out other causes
FDG-PET: Evaluate metabolic patterns in posterior regions
Amyloid PET: Confirm amyloid status
CSF analysis: Optional biomarker confirmation for atypical cases

A comprehensive diagnostic workup is essential to rule out other causes of visual impairment and confirm the diagnosis. [@crutch2022]

Differential Diagnosis

PCA must be distinguished from:

Typical Alzheimer's Disease: Memory prominent early, posterior atrophy less severe
Dementia with Lewy Bodies: Fluctuations, hallucinations, parkinsonism
Corticobasal Degeneration: Asymmetric apraxia, alien limb phenomena
Progressive Supranuclear Palsy: Vertical gaze palsy, postural instability
Posterior fossa lesions: Structural causes of visual symptoms
Posterior cortical lesions: Stroke, tumor, or other structural causes

The differential diagnosis includes both neurodegenerative and non-neurodegenerative conditions that can affect posterior brain regions. [@mendez2023]

Treatment

Current Approaches

Currently no disease-modifying treatments specifically for PCA exist. Management includes:

[Cholinesterase inhibitors](/entities/cholinesterase-inhibitors): Modest symptomatic benefit ([donepezil](/therapeutics/donepezil), [rivastigmine](/therapeutics/rivastigmine), galantamine) - may help with attention and visual processing [@rogers2016]
Visual aids and environmental modifications: Adaptive technologies, high-contrast displays, magnification devices
Occupational therapy: Strategies for daily living, environmental adaptations
Safety measures: Address visual impairment risks, fall prevention
Caregiver support: Education and support programs
Antidepressants: For associated depression and anxiety

Investigational Therapies

Disease-modifying therapies: Anti-amyloid and anti-tau agents under investigation - current trials include PCA patients [@hampton2022]
Tau-targeted approaches: Various agents in clinical trials targeting tau pathology
Symptomatic treatments: For specific symptom management
Rehabilitation approaches: Visual and cognitive rehabilitation strategies
Neuroprotective agents: Under investigation for slowing progression

Management Strategies

Environmental adaptations: Improve lighting, reduce clutter, use contrast, remove tripping hazards

Assistive technologies: Screen readers, voice assistants, adaptive software, GPS navigation aids

Psychological support: Address depression and anxiety, provide counseling

Caregiver education: Understanding the condition and progression, developing coping strategies

Vision rehabilitation: Low vision specialists, adaptive devices, training in visual compensatory strategies

Prognosis

PCA follows a progressive course over 8-12 years, with eventual spread to anterior brain regions. Visual symptoms are progressive and lead to significant functional impairment. Eventually, memory and other cognitive domains become affected as the disease progresses.

Key prognostic factors include:

Age of onset (younger onset may have slower progression)
Initial severity of symptoms
Pattern of atrophy on imaging
Presence of underlying AD pathology

Quality of life depends on early diagnosis, appropriate support, and environmental adaptations. [@crutch2023]

Research Directions

Current research focuses on:

Understanding pathological correlates: Amyloid and tau imaging studies
Identifying characteristic CSF biomarkers: Specific signatures for PCA
Genetic factors: [APOE](/genes/apoe) and other genetic associations
Treatment development: Disease-modifying therapies
Biomarker development: Early detection and progression markers
Network-based approaches: Understanding how degeneration spreads through brain networks
Clinical trial design: Optimizing trial endpoints for PCA-specific outcomes

Recent advances in understanding PCA have revealed distinct patterns of tau pathology and network dysfunction that differentiate it from typical AD. [@vogel2024]

Visual Pathway Diagram

Mermaid diagram (expand to render)

Key Pathways in PCA

Amyloid-β Targeting: Unlike typical AD, amyloid-β preferentially deposits in posterior brain regions

Tau Pathology Spread: Follows a pattern affecting visual processing areas first

Network Breakdown: Visual processing networks disintegrate before memory systems

Relationship to Other Neurodegenerative Diseases

Alzheimer's Disease

PCA is strongly associated with Alzheimer's disease:

Shared amyloid-beta and tau pathology in approximately 80% of cases
APOE4 carrier status as major risk factor
Similar predominant neuroinflammation mechanisms

Corticobasal Degeneration

Corticobasal Degeneration (CBD) shows clinical overlap with PCA:

Both are atypical parkinsonian syndromes
Shared 4R-tau pathology in some cases
Differential diagnosis is challenging

Dementia with Lewy Bodies

Dementia with Lewy Bodies may present with visual hallucinations:

Differentiated by alpha-synuclein pathology
Fluctuating cognition pattern
REM sleep behavior disorder association

Progressive Supranuclear Palsy

Progressive Supranuclear Palsy (PSP):

Vertical gaze palsy distinguishes from PCA
Both involve posterior cortical dysfunction
Different tau isoform pathology

Primary Progressive Aphasia

Primary Progressive Aphasia (PPA):

Language variant that may co-occur with PCA
Left hemisphere predominant atrophy
Different from PCA's posterior predilection

Neuropathology

Key Proteinopathies

Amyloid-beta plaques (present in approximately 80% of cases)
Tau neurofibrillary tangles (prominent, with posterior distribution)
AD-type pathology with posterior emphasis

Regional Atrophy Patterns

Occipital lobe and parietal lobe
Primary visual cortex relatively spared until late stages
Posterior cingulate involvement

Associated Molecular Changes

Neurotransmitter Deficits

Cholinergic system deficiency
[Acetylcholine](/acetylcholine) reduction
Reduced cholinesterase activity

Synaptic Dysfunction

Synaptic loss in visual processing areas
Neurotransmitter vesicle disruption
Impaired synaptic plasticity

Therapeutic Approaches

Cholinesterase Inhibitors

Standard AD therapeutics used:

Donepezil (Aricept)
[Rivastigmine](/therapeutics/rivastigmine) (Exelon)
Galantamine (Razadyne)

Symptomatic Treatments

Depression management (SSRIs)
Visual aid devices and low vision rehabilitation
Occupational therapy
Safety supervision and fall prevention

Emerging Therapies

Anti-amyloid therapies (Leqembi)
Anti-tau therapies
Neuroprotective agents
Neuroinflammation modulators

Management

Patient Support

Low vision rehabilitation services
Environmental modifications for safety
Caregiver education and support groups
Regular follow-up with neurology and ophthalmology

Monitoring

Regular cognitive assessment
Functional decline tracking
Visual function monitoring
MRI monitoring of atrophy progression

Management

Patient Support

Low vision rehabilitation services
Environmental modifications for safety
Caregiver education and support groups
Regular follow-up with neurology and ophthalmology

Monitoring

Regular cognitive assessment
Functional decline tracking
Visual function monitoring
MRI monitoring of atrophy progression

Clinical Assessment Tools

Neuropsychological Testing

Standard neuropsychological batteries for PCA include:

Visual perception tests: Object recognition, figure copying, spatial location tasks
Reading and writing assessments: Text reading, letter and word writing
Calculation testing: Basic arithmetic operations, number writing
Memory assessment: Verbal and visual memory (typically relatively preserved early)
Language testing: Naming, repetition, comprehension (typically preserved early)
Executive function: Set-shifting, planning (may be affected later)

Vision Testing

Comprehensive vision assessment includes:

Visual acuity testing (distance and near)
Visual field testing (confrontation and perimetry)
Color vision testing
Contrast sensitivity testing
Depth perception assessment
Motion perception testing

Emerging Research

Biomarker Development

Recent research has focused on developing PCA-specific biomarkers:

Retinal imaging: OCT to assess retinal nerve fiber layer thickness
Visual evoked potentials: Abnormalities in pattern reversal VEP
Sleep biomarkers: Changes in sleep architecture associated with PCA
olfactory dysfunction: May be less pronounced than in typical AD

Treatment Targets

Emerging treatment approaches include:

Tau-directed therapies: Anti-tau antibodies, small molecule tau aggregation inhibitors
Synaptic protection: Synaptic stabilizers and neurotrophic factors
Network modulation: Transcranial magnetic stimulation targeting visual networks
Visual rehabilitation: Computer-based visual training programs

Genetics

Ongoing genetic studies aim to identify:

Risk genes specific to PCA: Genes that may confer risk for posterior cortical degeneration
Modifiers of age of onset: Genetic factors influencing when symptoms begin
Progression modifiers: Genes that may affect rate of disease progression
Therapeutic targets: Genes that may be amenable to targeted therapy

Conclusion

Posterior Cortical Atrophy represents a distinct clinical syndrome within the Alzheimer's disease spectrum. Characterized by progressive visual processing deficits with relative preservation of memory and other cognitive functions early in the disease, PCA provides unique insights into the selective vulnerability of posterior brain regions in neurodegenerative diseases.

The diagnosis requires a comprehensive evaluation including detailed neuropsychological testing, neuroimaging, and biomarker assessment. While no disease-modifying treatments are currently available, ongoing research into anti-amyloid and anti-tau therapies offers hope for future disease-modifying interventions.

Management focuses on symptomatic treatment, environmental adaptations, and support for patients and caregivers. Early diagnosis is crucial for maximizing functional independence and quality of life.

Future research directions include the development of PCA-specific biomarkers, better understanding of the biological mechanisms underlying selective posterior cortical vulnerability, and the development of disease-modifying therapies targeting the underlying pathophysiology of this distinctive syndrome.

References

[Crutch SJ, et al., Posterior cortical atrophy. Lancet Neurol. 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28374828/)

[Mendez MF, et al., Posterior cortical atrophy: clinical characteristics and differences to Alzheimer's disease. Behav Neurol. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30661063/)

[Schott JM, et al., Consensus on posterior cortical atrophy. Lancet Neurol. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32092845/)

[Benson DF, et al., Posterior cortical atrophy: variant of Alzheimer's disease? A case series. Arch Neurol. 1988 (1988)](https://pubmed.ncbi.nlm.nih.gov/3340342/)

[Kas A, et al., The posterior cortical atrophy syndrome: clinical and neuroimaging correlates. J Neurol. 2013 (2013)](https://pubmed.ncbi.nlm.nih.gov/23681264/)

[Migliaccio R, et al., Apraxia of eyelid opening and posterior cortical atrophy. Parkinsonism Relat Disord. 2012 (2012)](https://pubmed.ncbi.nlm.nih.gov/22000979/)

[Matsumoto K, et al., MRI findings in posterior cortical atrophy. J Neuroimaging. 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/25287283/)

[Bae JR, et al., FDG-PET findings in posterior cortical atrophy. Dement Geriatr Cogn Disord. 2016 (2016)](https://pubmed.ncbi.nlm.nih.gov/27567031/)

[Fischer CE, et al., Resting state connectivity in posterior cortical atrophy. Neuroimage Clin. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31178599/)

[Safirstein B, et al., Tau pathology in posterior cortical atrophy. Acta Neuropathol. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32948095/)

[Whitwell JL, et al., Cholinergic deficiency in posterior cortical atrophy. Dement Geriatr Cogn Disord. 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28654903/)

[Caroppo P, et al., Genetic findings in posterior cortical atrophy. J Neurol. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30627901/)

[Miller ZA, et al., CSF biomarkers in posterior cortical atrophy. Neurology. 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29440473/)

[Cullen NC, et al., Plasma biomarkers in posterior cortical atrophy. Brain. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33561238/)

[Dubois B, et al., Diagnostic criteria for posterior cortical atrophy. Lancet Neurol. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33930389/)

[Crutch SJ, et al., Diagnostic workup of posterior cortical atrophy. Nat Rev Neurol. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35042912/)

[Mendez JC, et al., Differential diagnosis of posterior cortical atrophy. J Neuropsychiatry Clin Neurosci. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/36952356/)

[Rogers SL, et al., Cholinesterase inhibitor therapy in posterior cortical atrophy. Dement Geriatr Cogn Disord. 2016 (2016)](https://pubmed.ncbi.nlm.nih.gov/27160087/)

[Hampton OL, et al., Clinical trials in posterior cortical atrophy. Alzheimers Res Ther. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35440018/)

[Crutch SJ, et al., Prognosis in posterior cortical atrophy. J Neurol Neurosurg Psychiatry. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37478891/)

[Vogel JW, et al., Network-based degeneration in posterior cortical atrophy. Brain. 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38567023/)

📖 View canonical wiki page →

Related Entities

diseases-posterior-cortical-atrophy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-posterior-cortical-atrophy
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e007dd11329e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-posterior-cortical-atrophy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

55%

Debates

0

Incoming

11

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Posterior Cortical Atrophy

Posterior Cortical Atrophy

Introduction

Epidemiology

Clinical Presentation

Core Symptoms

Posterior Cortical Atrophy

Introduction

Epidemiology

Clinical Presentation

Core Symptoms

Balint's Syndrome

Gerstmann Syndrome

Additional Clinical Features

Disease Comparison

Neuroimaging

MRI Findings

PET Findings

Functional Connectivity

Pathophysiology

Underlying Pathology

Neurotransmitter Deficits

Genetic Factors

Biomarkers and Diagnostic Markers

Neuroimaging Biomarkers

CSF Biomarkers

Blood-Based Biomarkers

Diagnosis

Clinical Criteria

Diagnostic Workup

Differential Diagnosis

Treatment

Current Approaches

Investigational Therapies

Management Strategies

Prognosis

Research Directions

See Also

Visual Pathway Diagram

Key Pathways in PCA

Relationship to Other Neurodegenerative Diseases

Alzheimer's Disease

Corticobasal Degeneration

Dementia with Lewy Bodies

Progressive Supranuclear Palsy

Primary Progressive Aphasia

Neuropathology

Key Proteinopathies

Regional Atrophy Patterns

Associated Molecular Changes

Neurotransmitter Deficits

Synaptic Dysfunction

Therapeutic Approaches

Cholinesterase Inhibitors

Symptomatic Treatments

Emerging Therapies

Management

Patient Support

Monitoring

See Also

Management

Patient Support

Monitoring

Clinical Assessment Tools

Neuropsychological Testing

Vision Testing

Emerging Research

Biomarker Development

Treatment Targets

Genetics

Conclusion

References

💬 Discussion